

Health Care Market Oversight (HCMO) Program

HCMO-1: Notice of Material Change Transaction

You can get this document in other languages, large print, braille or a format you prefer free of charge. Contact us by email at hcmo.info@oha.oregon.gov or by phone at 503-945-6161. We accept all relay calls.

General Instructions

Pursuant to Oregon Revised Statute (ORS) 415.501, an entity to a material change transaction must submit a Notice to the Oregon Health Authority (OHA) notifying OHA of such transaction. This HCMO-1 Notice form must be used to comply with this statutory mandate. Please see [Technical Specifications for Submissions](#) for more information about the submission format and technical requirements. Please see the [HCMO guidance document](#) for sub-regulatory guidance and information about program requirements.

You must file this HCMO-1 Notice form electronically with OHA, in a portable document form (pdf), by email to hcmo.info@oha.oregon.gov **no less than 180 days** before the expected closing date of your material change transaction. Please submit the completed HCMO-1 Notice form, other relevant HCMO forms, and any supplemental documents as separate files.

To avoid delays in OHA's review of your proposed transaction, due diligence is required to complete this HCMO-1 Notice form correctly. This form should not contain any redacted information. Please provide a public-facing response to each item. The public facing response may reference a confidential appendix, as relevant. Pursuant to the requirements of OAR 409-070-0070(1), this form should not contain any information you intend to designate as confidential. All information you designate as confidential must be provided separately as one or more supplemental attachments to this form. To avoid unnecessary delays, do not redact content that is publicly available or without grounds for a claim of confidentiality under Oregon law. Please consistently apply Bates numbering to all documents submitted with this form and include the applicable Bates number sequence on all redaction logs.

The Notice is not complete until all required information is satisfactorily provided, and the review period will not run until OHA deems the Notice complete.

This HCMO-1 Notice form, along with any public supporting documents, will be published and serve as notice to the public. Contact program staff with any questions or to request technical assistance at hcmo.info@oha.oregon.gov.

Who must file a Notice

Under ORS 415.501, an entity entering into a transaction that constitutes a material change must submit written notice to OHA of such material change.

A material change transaction includes:

- A. A transaction in which at least one party had average revenue of \$25 million or more in the preceding three fiscal years and another party:
 - i. Had an average revenue of at least \$10 million in the preceding three fiscal years; or
 - ii. In the case of a new entity, is projected to have at least \$10 million in revenue in the first full year of operation at normal levels of utilization or operation as prescribed by the authority by rule.

For more information, see [Entities Subject to Review](#).

Out-of-state entities

If a transaction involves a health care entity in this state and an out-of-state entity, a transaction that otherwise qualifies as a material change transaction must submit this Notice if the transaction may result in increases in the price of health care or limit access to health care services in this state. See [OHA Guidance on Out-of-State Entities](#).

Optional Determination of Covered Transaction Status

To request that OHA determine whether a notice of material change transaction is required, parties may submit a [HCMO-4: Determination of Covered Transaction Status](#).

Confidentiality

Information on this HCMO-1 Notice form shall be a public record and will be posted on OHA's website. Pursuant to ORS 415.501(13), OHA shall maintain the confidentiality of all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction and may not disclose the information or documents to any person without the consent of the person who provided the information or document. Information and documents described in this paragraph are exempt from disclosure under Oregon Public Records Law (ORS 192.311 to 192.478).

Entities must follow the requirements of Oregon Administrative Rule (OAR) 409-070-0070 when designating portions of a Notice and any documents submitted by the applicant in support of the Notice as confidential. See [OHA Use of Confidential Information Guidance](#).

Definitions

“**Acquisition**” occurs when:

- a) Another person acquires control of the health care entity including acquiring a controlling interest as described in OAR 409-070-0025;
- b) Another person acquires, directly or indirectly, voting control of more than fifty percent (50%) of any class of voting securities of the health care entity other than a domestic insurer as described in OAR 409-070-0025(1)(c);

- c) Another person acquires all or substantially all of the health care entity's assets and operations;
- d) Another person undertakes to provide the health care entity with comprehensive management services; or
- e) The health care entity merges tax identification numbers or corporate governance with another entity.

“Legal entity name” means legal business name as reported with Internal Revenue Service.

“Merger” means a consolidation between two or more organizations, including two or more organizations joining through a common parent organization or two or more organizations forming a new organization.

“NPI” means 10-digit National Provider Identification number issued by the Centers for Medicare and Medicaid Services (CMS).

“Tax ID” means 9-digit federal tax identification number also known as an employer identification number (EIN) assigned by the Internal Revenue Service.

“Transaction” means:

- a) A merger of a health care entity with another entity;
- b) An acquisition of one or more health care entities by another entity;
- c) New contracts, new clinical affiliations and new contracting affiliations that will eliminate or significantly reduce, as defined by the authority by rule, essential services (see [Essential Services and Significant Reduction](#) guidance);
- d) A corporate affiliation involving at least one health care entity; or
- e) Transactions to form a new partnership, joint venture, accountable care organization, parent organization or management services organization.

“Ultimate Parent Entity” means an entity which is not controlled by any other entity.

Additional defined terms can be found at ORS 415.500 et seq. and OAR 409-070-0000 to -0085.

I. Parties to the proposed transaction

1. Provide the requested information for all parties to the proposed transaction. Provide information for Party A, including information for a public-facing contact.

Legal Entity Name	Hanger, Inc.
Assumed Entity Name	Not applicable.
Website	www.corporate.hanger.com
Public Contact Name	Thomas Hartman, General Counsel
Public Contact Email	THartman@hanger.com

2. Provide information for Party B, including information for a public-facing contact.

Legal Entity Name	United Seating and Mobility, L.L.C.
Assumed Entity Name	Numotion
Website	www.numotion.com
Public Contact Name	Timothy Casey, General Counsel
Public Contact Email	timothy.casey@numotion.com

3. Are there additional Parties to the proposed transaction? For any additional Parties, please provide a public-facing supplemental attachment describing the information requested in Section I.

☐ Yes

☒ No

II. About the proposed transaction

4. Provide the type of material change transaction. (See OAR 409-070-0010 for definitions of transactions subject to review.)

☐ Merger

☒ Acquisition

☐ Affiliation

☐ Contract

☐ Other (specify)_____

5. What is the anticipated effective date of the proposed material change transaction?

The parties anticipate closing as quickly as practicable following receipt of all required regulatory approvals.

6. Describe the proposed material change transaction, including:

a. Goals and objectives

Numotion and Hanger are both committed to serving individuals with disabilities and mobility limitations. Numotion's core business focuses on Complex Rehabilitation Technology, including individually configured mobility equipment, related service and repair, speech solutions, medical supplies, and retail mobility products. Hanger operates its business through various subsidiaries, and its largest business, Hanger Clinic, provides orthotic and prosthetic ("O&P") patient care services, while its products and services segment includes the distribution, manufacture, and fabrication of O&P devices and components. The parties will continue to serve customers under their existing brands following the close of the transaction and maintain their respective clinical operations so they can continue to serve the community.

The parties believe the transaction can support continued investment in customer service, clinical and operational capabilities, technology, compliance infrastructure, product access, and service delivery. The objective is to improve the experience of individuals who rely on customized mobility, orthotic, prosthetic, and related products by preserving access and quality while strengthening each organization's ability to respond to increasingly complex documentation, reimbursement, supply-chain, and service requirements.

b. Summary of transaction terms. The summary should align with the submitted transaction term sheet or agreement.

The transaction is structured as an equity purchase, pursuant to which Hanger will acquire 100% of the equity interests of NMN Holdings I Corp. ("NMN"). Following closing of the transaction, Numotion will become an indirect subsidiary of Hanger. As currently contemplated, the transaction will take place several levels above the operating entities and involve only NMN and Hanger and will not be a merger of Numotion into one of Hanger's existing businesses.

Numotion expects its operational structure and functions to remain largely unchanged after closing. Following the closing of the transaction, Hanger's existing clinical operations, personnel and compliance program are expected to remain separate from Numotion's business.

c. Why the transaction is necessary or warranted

The transaction is warranted because organizations serving individuals with complex mobility and functional needs face demanding operational, reimbursement, documentation, technology, supply-chain, compliance, and service requirements. Numotion's CRT workflow requires coordination among the customer, treating practitioners, physical or occupational therapists, assistive technology professionals, manufacturers, payers, and service personnel. The process commonly includes functional evaluation, physician involvement, prior authorization, manufacturer customization, delivery, fitting, and follow-up documentation. Hanger provides orthotic and prosthetic patient care services, distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to the broader post-acute market.

The proposed transaction is intended to support sustained investment in these capabilities and to combine complementary experience in customized products, clinical support, service delivery, product distribution, compliance, and customer advocacy. The objective is to strengthen each party's ability to meet customer needs and maintain reliable access to medically necessary products and services.

- d. Any exchange of funds between the parties, including the nature, source and amount of funds or other consideration (such as purchase price, any arrangement in which one party agrees to furnish the other party with a discount, rebate, or any other type of refund or remuneration in exchange for, or in any way related to, the provision of health care services). Please quantify any amounts, such as purchase price, price per share, number or percent of shares, etc.**

The consideration for this transaction is set forth under Section 1.3 and Article X of the Stock Purchase Agreement and does not include any discount, rebate or any other type of refund or remuneration in exchange for, or in any way related to, the provision of health care services.

7. Describe the negotiation or transaction process that resulted in the entities entering into an agreement.

Hanger had the opportunity to evaluate Numotion on a proprietary basis. They first began discussions with Numotion in early-Spring 2026. They engaged with Numotion and its investment banker, Jefferies, periodically thereafter, and submitted an initial IOI on May 29, 2026. They eventually reached a handshake agreement in July 2026 and began progressing the transaction in earnest. The parties signed the Stock Purchase Agreement and related transaction documents on September 9, 2026 where the closing of the transaction will occur as quickly as practicable following receipt of applicable regulatory approvals.

- a. How the entities were identified (e.g., did one party approach the other, did one party engage in a bid/auction process)**

As mentioned in Response 7, Hanger had the opportunity to evaluate Numotion on a proprietary basis and engaged with Numotion and its investment banker, Jefferies.

b. Any due diligence performed by any of the parties to the transaction. Provide any products, reports, or analyses resulting from due diligence processes.

Hanger conducted customary due diligence covering, among other areas, Numotion's corporate organization and governance, financial performance, business operations, customer service, reimbursement, healthcare regulatory compliance, licensure and enrollment, payer contracting, litigation, employment, technology, information security and privacy, insurance, real estate, material contracts, and environmental and other operational matters. Numotion provided information and documents through the transaction data room and participated in management and subject-matter discussions concerning the business and its operations. The diligence process also included evaluation of healthcare regulatory filing requirements.

c. Any other alternatives that were explored, including bids or offers from other entities.

No other alternatives were explored during the period of time that Hanger was identified.

8. Will the proposed material change transaction change control of a public benefit corporation or religious corporation?

☐ Yes

☒ No

9. List any applications, forms, notices, or other materials that have been submitted to any other state or federal agency regarding the proposed material change transaction. Include the data and nature of any submissions. This includes, but is not limited to, the Oregon Department of Consumer and Business Services, Oregon Public Health Division, Oregon Department of Justice, U.S. Department of Health and Human Services (e.g., Pioneer ACO or Medicare Shared Savings Program application), Federal Trade Commission, and U.S. Department of Justice.

The parties have identified healthcare regulatory filing or notice requirements in California, Indiana, Massachusetts, Minnesota, North Carolina, and Oregon as set forth under Schedule 2.6(b) of the Disclosure Schedules of the Stock Purchase Agreement. Copies of applications, notices, forms, and supplemental materials

submitted in connection with the proposed transaction can be provided upon request.

- a. If a pre-merger notification was filed with the Federal Trade Commission or U.S. Department of Justice, please attach the pre-merger notification filing and attachments along with this notice submission.**

Not applicable.

- b. If Parties have not yet filed a pre-merger notification, but expect to, please provide a timeline for that filing. Once a pre-merger notification is filed, please submit it to OHA.**

Pursuant to the terms of the Stock Purchase Agreement, the parties are required to file HSR within 10 business days of the signing, which is September 23, 2026.

III. About the entities involved in the proposed transaction

- 10. Describe Party A. In the responses, include information for any parent or subsidiary entities, including the ultimate parent entity.**

Hanger, Inc. is owned by affiliates of Patient Square Capital, LP (“Patient Square”). Hanger’s ultimate parent company is PSC Hero Holdings, LP, a Delaware limited partnership.

- a. Describe Party A’s business, including business lines or segments**

Hanger provides O&P patient care services, distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to the broader post-acute market. Hanger has two operating segments: (i) Patient Care and (ii) Products & Services. Hanger’s Patient Care segment is comprised of Hanger Clinic. Hanger’s Products & Services segment is comprised of its distribution business, O&P product manufacturing and fabrication businesses and rehabilitative solutions business.

- b. Describe Party A’s governance and operational structure (including ownership of or by a health care entity). Please include information about any owners or investors with 10% or greater ownership interest in Party A.**

Hanger is owned by affiliates of Patient Square. Hanger’s ultimate parent company is PSC Hero Holdings, LP, a Delaware limited partnership (“Topco”). The board at Topco is the central governing board of the entity structure, including Hanger. General day-to-day operations are handled at the Hanger and subsidiary levels.

- c. Provide a diagram or chart showing the organizational structural and relationships between business entities. Include all parent, subsidiary, and associated entities. Please include all owners or investors with at least 10%**

ownership interest and label the chart with the percent ownership interest. Owners or investors with less than 10% ownership interest may be represented collectively on the organizational chart.

Please see [HNG-00025_Hanger Organizational Chart](#).

- d. Complete a [HCMO-1 Workbook](#) for Party A, providing the following information:
- i. Provide organization National Provider Identifiers for any Party A facilities, locations, companies, or subsidiaries providing services in Oregon;
 - ii. List all of Party A's business entities currently licensed to operate in Oregon;
 - iii. List all of Party A's facilities owned or operating in Oregon; and
 - iv. Provide data on Party A's staffing and services for the most recent twelve-month period.

Please see [HNG-00023_HCMO-1-Workbook - Hanger](#).

- e. Provide financial statements for the most recent three fiscal years. If Party A also operates outside of Oregon, provide financial statements both for Party A nationally and for Party A's Oregon business. If audited financial statements are not available, please provide the most complete documentation possible.

Please see [HNG-00255_Hanger 2023 Annual Financials](#), [HNG-00328_Hanger 2024 Annual Financials](#), and [HNG-00401_Hanger 2025 Annual Financials](#).

- f. Describe and identify Party A's health care business in Oregon and for all business inside and outside Oregon. Provide responses to i-v as applicable, including for any parent and subsidiary entities:

Click or tap here to enter text.

i. Provider types (hospital, physician group, etc.)

Prosthetic and custom orthotic patient care services delivered through clinics.

ii. Service lines, both overall and in Oregon

The provision of O&P services and devices to patients; the distribution or fabrication of O&P devices, components, and parts for businesses; the provision of therapeutic treatment solutions and related equipment to businesses in acute, post-operative, and clinic settings; and the manufacture of O&P components, parts, and devices for businesses.

iii. Products and services, both overall and in Oregon

Prosthetic and orthotic patient care services; distribution of O&P components, parts, and materials; manufacturing of O&P components and parts; rehabilitation treatment modalities; and related equipment.

iv. Geographic areas served, both overall and in Oregon

All 50 United States, plus the District of Columbia and the U.S. Virgin Islands.

v. For hospitals, number of licensed beds

Not applicable.

11. Describe Party B. In the responses, include information for any parent or subsidiary entities, including the ultimate parent entity.

a. Describe Party B's business, including business lines or segments

United Seating and Mobility, L.L.C., doing business as Numotion, is a provider of durable medical equipment and supplies, with a primary focus on Complex Rehabilitation Technology. Numotion provides individually configured, medically necessary mobility products and related services to individuals with complex medical and functional needs. Its business includes Complex Rehabilitation Technology equipment, equipment service and repair, speech solutions, medical supplies, and retail mobility products. Numotion's core CRT process involves coordination with independent physicians and physical or occupational therapists who evaluate the customer and establish medical need. Numotion supports order intake, benefits and funding review, product configuration, documentation, procurement, delivery, fitting, repair, and ongoing service. Numotion does not employ the licensed healthcare providers who make the underlying clinical referrals. Numotion operates five locations in Oregon: Central Point, Redmond, Salem, Springfield, and Tualatin.

b. Describe Party B's governance and operational structure (including ownership of or by a health care entity). Please include information about any owners or investors with 10% or greater ownership interest in Party B.

Numotion's principal operating company is United Seating and Mobility, L.L.C. The business is held through a multi-tier parent-company structure that includes NMN Holdings LP and intermediate holding companies. Numotion operates through the principal operating company and subsidiaries and affiliated businesses supporting its Complex Rehabilitation Technology, retail, medical-supplies, speech, and related operations. The company is overseen by a board of directors and managed by a senior executive team led by its Chief Executive Officer. The organization maintains centralized corporate functions and field and operational leadership responsible for customer-facing operations.

- c. **Provide a diagram or chart showing the organizational structural and relationships between business entities. Include all parent, subsidiary, and associated entities. Please include all owners or investors with at least 10% ownership interest and label the chart with the percent ownership interest. Owners or investors with less than 10% ownership interest may be represented collectively on the organizational chart.**

Please see **HNG-00028_Numotion Organizational Chart**.

- d. **Complete a [HCMO-1 Workbook](#) for Party B, providing the following information:**
- i. **Provide organization National Provider Identifiers for any Party B facilities, locations, companies, or subsidiaries providing services in Oregon;**
 - ii. **List all of Party B's business entities currently licensed to operate in Oregon;**
 - iii. **List all of Party B's facilities owned or operating in Oregon; and**
 - iv. **Provide data on Party B's staffing and services for the most recent twelve-month period.**

Please see **HNG-00024_HCMO-1-Workbook - Numotion**.

- e. **Provide financial statements for the most recent three fiscal years. If Party B operates outside of Oregon, provide financial statements both for Party B nationally and for Party B's Oregon business.**

Please see **HNG-00466_Numotion 2023 Annual Financials**, **HNG-00492_Numotion 2024 Annual Financials**, and **HNG-00516_Numotion 2025 Annual Financials**.

- f. **Describe and identify Party B's health care business. Provide responses to i-v as applicable, including for any parent and subsidiary entities.**

Click or tap here to enter text.

- i. **Provider type (hospital, physician group, etc.)**

Numotion is a DME supplier with a primary focus on Complex Rehabilitation Technology. It is not a hospital, physician group, or licensed clinical practice. Independent treating practitioners and physical or occupational therapists establish medical need and make referrals; Numotion supplies and services prescribed equipment.

- ii. **Service lines, both overall and in Oregon**

Complex Rehabilitation Technology equipment, service and repair, ancillary health services, speech solutions, medical supplies, and retail mobility products.

iii. Products and services, both overall and in Oregon

Complex Rehabilitation Technology equipment; service and repair; speech solutions; medical supplies; and retail mobility products.

iv. Geographic areas served, both overall and in Oregon

Numotion operates locations in Central Point, Redmond, Salem, Springfield, and Tualatin, Oregon. Oregon geographic service area will be provided based on Operations and the current location/service-area master.

v. For hospitals, number of licensed beds

Not applicable.

12. For any additional Parties, please provide a supplemental attachment describing the information requested in Section 11 (a) – (f).

Not applicable.

13. Describe all health care mergers, acquisitions, and joint ventures that closed in the ten (10) years prior to filing this notice of material change transaction involving any entities party to the current proposed transaction and any entities providing related services in Oregon, including any parent or subsidiary entities. Include all transactions, regardless of whether they were subject to HCMO review. For each previous transaction, include:

- a. Legal names of all entities party to the transaction
- b. Type of transaction
- c. Description of the transaction
- d. Date the transaction closed

Hanger does not have any transactions to disclose in response to Question No. 13. Please see **HNG-00807_Numotion Summary of Prior Transactions** for a list of Numotion's transactions in response to Question No. 13.

14. Describe whether the parties to the transaction offer similar services or operate in overlapping geographic areas.

The parties do not offer the same services and therefore do not have a product or geographic overlap. Hanger provides orthotic and prosthetic patient care services through Hanger Clinic and also distributes, manufactures, and fabricates O&P devices, components, and related products. Numotion provides durable medical equipment and supplies, with a primary focus on Complex Rehabilitation Technology, including individually configured mobility equipment, service and repair, speech solutions, medical supplies, and retail mobility products. While both parties offer their respective services in Oregon, their services are different and there is no competitive overlap.

- a. **Provide applicable data, metrics, or documentation to support your statements.**

Not applicable.

IV. Impacts from the proposed material change transaction

15. Describe any anticipated changes resulting from the proposed material change transaction, including:

- a. **Operational structure**

- i. **Provide a chart or diagram showing the pre- and post-transaction organizational structure and relationships between entities. Please include all owners or investors with at least 10% ownership interest and label the chart with the percent ownership interest. Owners or investors with less than 10% ownership interest may be represented collectively on the organizational chart.**

Please see **HNG-00025_Hanger Organizational Chart**, **HNG-00028_Numotion Organizational Chart**, and **HNG-00029_Post-Close Organizational Chart**.

- b. **Corporate governance and management**

At the operational level there will be no changes to the corporate governance or management of Numotion as a result of this transaction. Following the closing of the transaction Numotion will be a wholly owned subsidiary of Hanger and as such, the board of managers of Topco will be the central governing board of Numotion as well as Hanger.

- c. **Investments or initiatives**

There are no planned investments or initiatives at this time.

- d. **Type and level of staffing**

The parties do not expect any changes to Numotion's staffing as a result of this transaction.

- e. **Type and level of services provided**

The parties do not anticipate reducing the type or level of services available to Oregon customers as a result of the transaction. Numotion is expected to continue providing CRT, service and repair, and related products and services through its licensed operating entities and locations. Hanger will continue to operate in Oregon in ordinary course and consistent with its operations prior to closing of the transaction.

- f. **Number and type of locations**

There will be no changes to the number or type of locations operated by Numotion in Oregon as a result of the transaction.

g. Geographic areas served

There will be no changes to the geographic areas served as a result of the transaction.

h. For providers, payer contracts and payer mix

There will be no changes to the payer contracts and payer mix as a result of the transaction.

i. For insurance carriers, provider contracts and networks

Not applicable.

j. Other contractual arrangements, including contracts with suppliers, partners, ancillary service providers, PBMs, or management services organizations

The parties do not expect there to be any changes to any material contractual arrangements as a result of this transaction.

16. Describe how the transaction will benefit the public good in Oregon.

The transaction is intended to support continued access to medically necessary mobility products and related services for Oregon residents with disabilities and mobility limitations. Numotion's customers often rely on individually configured equipment for mobility, independence, participation in everyday life, and access to work, education, healthcare, and community activities. The parties expect the transaction to support continued investment in product access, order processing, service and repair, technology, compliance, customer communication, and employee capabilities.

17. Describe whether and how the transaction satisfies one or more of the preliminary review approval criteria, per OAR 409-070-0055.

a. Please indicate which criteria the Parties believe are met by the proposed transaction. Provide a detailed explanation of why the proposed transaction meets the selected criteria, along with any applicable data, metrics, or documentation to support claims.

☐ The material change transaction is in the interest of consumers and is urgently necessary to maintain the solvency of an entity involved in the transaction.

☒ The material change transaction is unlikely to substantially reduce access to affordable health care in Oregon.

☐ The material change transaction is likely to meet the criteria set forth in OAR 409-070-0060

☒ The material change transaction is not likely to substantially alter the delivery of health care in Oregon

☒ Comprehensive review of the material change transaction is not warranted given the size and effects of the transaction.

b. Provide a detailed explanation of why the proposed transaction meets the selected criteria, along with any applicable data, metrics, or documentation to support claims.

Given that Numotion expects its operational structure and functions to remain largely unchanged after closing, the parties do not believe the transaction will substantially reduce access to affordable health care in Oregon or substantially alter the delivery of health care in Oregon. Accordingly, comprehensive review of the material change transaction is not warranted given the limited effect of the transaction.

18. Describe the proposed material change transaction's impact on the financial stability of any entity involved in the transaction.

The parties expect the transaction to support the long-term financial stability and capacity for continued investment in customer service, operations, technology, compliance, and employee capabilities. The transaction is not expected to impair either company's ability to continue serving Oregon customers or meeting its obligations.

V. Supplemental materials

Submit the following materials, if applicable, with your submission. Apply Bates numbering to all confidential documents submitted with the Notice and include the applicable Bates number sequence on all redaction logs.

- ☒ [HCMO-1 Workbook](#) (provide a separate workbook for each party listed in Section I of this notice).
- ☒ [HCMO-5: Contact Information](#) form
- ☒ Pre- and post-transaction organizational structure diagram
- ☒ Copies of all current agreements or term sheets for the proposed transaction
- ☒ Financial statements for all entities for the most recent three fiscal years
- ☒ Copies of current governance documents for each party listed in Section I. of this notice (bylaws, articles of incorporation, corporate charter, etc.).
- ☒ Documentation or analytic support for your responses, as applicable
- ☒ [Document Index](#)
- ☒ Redaction log (See [Redaction Log Template](#) for required information.)

VI. Certification

I, the undersigned, being first duly sworn, do say:

1. I have read ORS 415.500 et seq. and OARs 409-070-0000 to 409-070-0085.
2. I have read this Notice of Material Change Transaction and the information contained therein is accurate and true.

Signed on the 21st day of September, 2026.



Thomas Hartman, Senior Vice President,
General Counsel and Secretary of
Hanger, Inc.

SUBSCRIBED AND SWORN TO before me, this 21st day of September, 2026.



Notary Public in and for Travis County, Texas



My Commission Expires: 02-18-2028